Florida

The most important recent Florida policy development for this topic is the 2025 mushroom spore/mycelium restriction in SB 700. Practically, that raises legal risk around spores and cultivation inputs even though it does not change the already-prohibited status of psilocybin/psilocin themselves.###

This means Florida’s “access” story is not about state reform. It is about ordinary controlled-substance medicine for ketamine/esketamine, sponsor-run research, and private provider availability. No verified statewide local deprioritisation framework surfaced in the official sources reviewed here.###

Florida’s strongest verified psychedelic research signal is now USF Health. Its psychiatry trials pages say the department is running psychedelic medication studies and specifically lists the atai ELUMINA trial for treatment-resistant depression and the REUNION ADCO study for adjustment disorder associated with serious medical illness. ClinicalTrials.gov identifies ELUMINA as VLS‑01 buccal film DMT in treatment-resistant depression, and identifies RE104 as the investigational product in the adjustment-disorder study.###

Florida also has ketamine research activity at Mayo Clinic in Jacksonville. Mayo lists a randomised ketamine-infusion trial in clinically depressed ICU patients and a related PTSD follow-up study in ICU survivors receiving subanaesthetic ketamine during hospitalisation. That is lawful research or medical ketamine work, not a state psychedelic-access route.###

There is no Florida rulemaking track for psilocybin services, facilitator licensing, service-centre licensing or state therapeutic access. The state’s clearest implementation action in 2025 was the creation of a new offence around spores and mycelium capable of producing mushrooms containing controlled substances.###

Operationally, the market therefore splits into three lanes: ordinary medical ketamine/esketamine care, sponsor-led clinical trials and enforcement. Provider availability may be meaningful in metropolitan areas, but there is no state-managed safety-monitoring or reporting system specific to psychedelic-assisted treatment analogous to Oregon- or Colorado-style service regimes.###

USF Health is the most important verified Florida institutional node in this review. It is publicly recruiting for psychedelic medication studies and has established internal clinical-trial infrastructure around depression and related psychiatric indications. Mayo Clinic Jacksonville contributes a second important node through ketamine-related research.###

On the care side, Florida’s ecosystem is provider-led rather than policy-led. Baptist Jacksonville offers SPRAVATO, and the Florida health-facility profile confirms ketamine-focused private practice activity in Miami. That points to a reasonably developed interventional psychiatry ecosystem, but not to any regulated psychedelic-services sector.###

Over the next 12–24 months, Florida is more likely to expand via research and private interventional psychiatry than through statutory reform. The most concrete near-term growth vector is sponsor-led trial activity at institutions such as USF Health, alongside continued ketamine/esketamine delivery in established psychiatric settings.###

For policy watchers, the main Florida signal is still caution rather than liberalisation. Unless a new bill changes the framework, patient access will remain limited to REMS esketamine, off-label ketamine and research enrolment, while the 2025 spores/mycelium provision suggests the state is prepared to tighten, not relax, parts of the psychedelic supply chain.###